These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.

Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.

The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.